We are live on
!
Find out more
NC
Nexthera Capital Portfolio holdings
AUM
$120M
1-Year Est. Return
10.01%
This Fund
S&P 500
This Quarter
Est. Return
+5.16%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$230M
AUM Growth
+$33.5M
(+17%)
Cap. Flow
+$27.2M
Cap. Flow
% of AUM
11.87%
Top 10 Holdings %
Top 10 Hldgs %
55.53%
Holding
52
New
16
Increased
8
Reduced
12
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$9.17M |
| 2 |
IPXL
Impax Laboratories, Inc.
IPXL
|
+$8.28M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$6.71M |
| 4 |
Aclaris Therapeutics
ACRS
|
+$6.21M |
| 5 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
+$4.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$14.5M |
| 2 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
+$3.02M |
| 3 |
CELG
Celgene Corp
CELG
|
+$2.56M |
| 4 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
+$2.21M |
| 5 |
TVRD
Tvardi Therapeutics
TVRD
|
+$2.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SHPG
1
DELISTED
Shire pic
SHPG
| $16.8M | 7.31% |
101,500
-2,500
| -2% | -$437K |
|
2
CALL
AstraZeneca
AZN
$263B
| $16.7M | 7.28% |
245,000
| – | – |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
| $14.6M | 6.36% |
120,000
+33,500
| +39% | +$3.9M |
|
4
GSK
GSK
$102B
| $13.9M | 6.05% |
257,600
+4,400
| +2% | +$235K |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $12.9M | 5.61% |
99,110
-20,890
| -17% | -$2.56M |
|
|
6
Pfizer
PFE
$142B
| $11.8M | 5.12% |
368,932
-458,512
| -55% | -$14.5M |
|
|
KITE
7
CALL
DELISTED
Kite Pharma, Inc.
KITE
| $11.4M | 4.97% |
+110,000
| New | +$8.98M |
|
|
KITE
8
DELISTED
Kite Pharma, Inc.
KITE
| $10.4M | 4.52% |
100,000
-5,000
| -5% | -$408K |
|
|
NDRM
9
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $9.78M | 4.26% |
327,240
+39,240
| +14% | +$1.02M |
|
|
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $9.3M | 4.05% |
340,100
+135,600
| +66% | +$4.03M |
|
|
11
Aclaris Therapeutics
ACRS
$795M
| $9.22M | 4.02% |
340,000
+228,500
| +205% | +$6.21M |
|
|
12
BioMarin Pharmaceuticals
BMRN
$11.4B
| $9.15M | 3.99% |
+100,800
| New | +$9.17M |
|
|
IPXL
13
DELISTED
Impax Laboratories, Inc.
IPXL
| $9.02M | 3.93% |
+560,400
| New | +$8.28M |
|
|
14
Alnylam Pharmaceuticals
ALNY
$36.2B
| $8.38M | 3.65% |
+105,000
| New | +$6.71M |
|
15
Vanda Pharmaceuticals
VNDA
$330M
| $7.53M | 3.28% |
462,200
-50,000
| -10% | -$721K |
|
|
TSRO
16
PUT
DELISTED
TESARO, Inc.
TSRO
| $6.99M | 3.05% |
50,000
| – | – |
|
|
ARRY
17
CALL
DELISTED
Array Biopharma Inc
ARRY
| $6.7M | 2.92% |
800,000
| – | – |
|
18
Minerva Neurosciences
NERV
$209M
| $5.09M | 2.22% |
71,875
-22,775
| -24% | -$1.47M |
|
|
FLXN
19
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $4.66M | 2.03% |
+230,500
| New | +$4.8M |
|
|
DOVA
20
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $4.42M | 1.92% |
+198,059
| New | +$4.17M |
|
|
DERM
21
DELISTED
Dermira, Inc.
DERM
| $3.51M | 1.53% |
+120,600
| New | +$3.67M |
|
22
Insmed
INSM
$23.5B
| $2.75M | 1.2% |
+160,000
| New | +$2.73M |
|
|
RXDX
23
DELISTED
Ignyta, Inc.
RXDX
| $2.59M | 1.13% |
250,000
-85,000
| -25% | -$690K |
|
|
STDY
24
DELISTED
SteadyMed Ltd
STDY
| $2.27M | 0.99% |
360,626
+355,227
| +6,579% | +$2.42M |
|
25
Abeona Therapeutics
ABEO
$372M
| $2.27M | 0.99% |
14,160
-5,603
| -28% | -$764K |
|
Similar funds
KAM
VCP
PFC
FCA
TA
EBIM
BCM
ACP
Nexthera Capital's Q2 2017 Portfolio in Review
As of Q2 2017, Nexthera Capital held 52 positions worth $230M, up 17% from $196M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Nexthera Capital deployed $27.2M of net new capital in Q2 2017, opening 16 new positions and adding to 8 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 100,800 shares worth $9.15M.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 70% a quarter earlier.
On the sell side, the largest reduction was Pfizer, an estimated $14.5M trimmed.
- Nexthera Capital's largest Q2 2017 buy was BioMarin Pharmaceuticals: 100,800 shares worth $9.15M.
- Nexthera Capital added most to Aclaris Therapeutics in Q2 2017, an estimated $6.21M increase.
- Nexthera Capital's biggest Q2 2017 reduction was Pfizer, cutting an estimated $14.5M.
- Nexthera Capital fully exited Eiger BioPharmaceuticals, Inc. in Q2 2017, selling an estimated $3.02M.
- Nexthera Capital's ten largest holdings make up 56% of its $230M portfolio in Q2 2017.
- Nexthera Capital opened 16 new positions and closed 11 in Q2 2017.
- Nexthera Capital's portfolio value rose 17% quarter-over-quarter to $230M.
Based on Nexthera Capital's 13F filing for Q2 2017, filed 14 Aug 2017.